BR112014009760B1 - Análogos de ácido siálico, seu uso e composição farmacêutica - Google Patents

Análogos de ácido siálico, seu uso e composição farmacêutica Download PDF

Info

Publication number
BR112014009760B1
BR112014009760B1 BR112014009760-7A BR112014009760A BR112014009760B1 BR 112014009760 B1 BR112014009760 B1 BR 112014009760B1 BR 112014009760 A BR112014009760 A BR 112014009760A BR 112014009760 B1 BR112014009760 B1 BR 112014009760B1
Authority
BR
Brazil
Prior art keywords
compound
group
sialic acid
acid
structural formula
Prior art date
Application number
BR112014009760-7A
Other languages
English (en)
Portuguese (pt)
Other versions
BR112014009760A2 (pt
BR112014009760A8 (pt
Inventor
Emil Kakkis
Steven Jungles
He Zhao
Original Assignee
Ultragenyx Pharmaceutical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ultragenyx Pharmaceutical Inc filed Critical Ultragenyx Pharmaceutical Inc
Publication of BR112014009760A2 publication Critical patent/BR112014009760A2/pt
Publication of BR112014009760A8 publication Critical patent/BR112014009760A8/pt
Publication of BR112014009760B1 publication Critical patent/BR112014009760B1/pt

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
    • C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
    • C07H13/10—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals directly attached to heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
    • C07H7/02—Acyclic radicals
    • C07H7/027—Keto-aldonic acids

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
BR112014009760-7A 2011-10-24 2012-10-24 Análogos de ácido siálico, seu uso e composição farmacêutica BR112014009760B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161550610P 2011-10-24 2011-10-24
US61/550.610 2011-10-24
PCT/US2012/061737 WO2013063149A1 (en) 2011-10-24 2012-10-24 Sialic acid analogs

Publications (3)

Publication Number Publication Date
BR112014009760A2 BR112014009760A2 (pt) 2017-04-18
BR112014009760A8 BR112014009760A8 (pt) 2018-01-16
BR112014009760B1 true BR112014009760B1 (pt) 2022-11-29

Family

ID=48168447

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112014009760-7A BR112014009760B1 (pt) 2011-10-24 2012-10-24 Análogos de ácido siálico, seu uso e composição farmacêutica

Country Status (13)

Country Link
US (5) US8840926B2 (enExample)
EP (1) EP2771348B1 (enExample)
JP (1) JP6196224B2 (enExample)
KR (1) KR102049214B1 (enExample)
CN (1) CN103974965B (enExample)
AU (1) AU2012328874B2 (enExample)
BR (1) BR112014009760B1 (enExample)
CA (1) CA2849114C (enExample)
ES (1) ES2807890T3 (enExample)
HK (1) HK1201067A1 (enExample)
IL (1) IL231714B (enExample)
MX (1) MX347541B (enExample)
WO (1) WO2013063149A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
JP5777712B2 (ja) 2010-07-13 2015-09-09 ウルトラジェニックス ファーマシューティカル インコーポレイテッド シアル酸欠乏症を治療するための方法および製剤
CA2849114C (en) 2011-10-24 2020-12-15 Ultragenyx Pharmaceutical Inc. Sialic acid analogs
BR112014017587A8 (pt) * 2012-01-18 2017-07-04 Ultragenyx Pharmaceutical Inc métodos e formulações para o tratamento de deficiências de ácido siálico
AR106025A1 (es) 2015-09-14 2017-12-06 Ultragenyx Pharmaceutical Inc Formas cristalinas de ácido siálico o una sal o solvato de este
WO2024173797A1 (en) * 2023-02-17 2024-08-22 Ultragenyx Pharmaceutical Inc. Crystalline forms of sialic acid derivatives and methods for their use

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6168418A (ja) 1984-09-11 1986-04-08 Kanto Ishi Pharma Co Ltd 去痰薬
JPS63139193A (ja) * 1986-11-28 1988-06-10 Mect Corp シアル酸誘導体１，７−ラクトン
US6156544A (en) 1993-06-09 2000-12-05 Glaxo Group Limited Process for the preparation of N-acetylneuraminic acid
CA2215978A1 (en) 1995-04-04 1996-10-10 Wound Healing Of Oklahoma Cancer treatment by photodynamic therapy, in combination with an immunoadjuvant
US5624677A (en) 1995-06-13 1997-04-29 Pentech Pharmaceuticals, Inc. Controlled release of drugs delivered by sublingual or buccal administration
ATE479425T1 (de) 1998-04-10 2010-09-15 Mitsubishi Chem Corp Sialsäure-derivate enthaltende feste dispersion
KR20030006721A (ko) 2001-07-14 2003-01-23 삼성전자 주식회사 리소그라피 시스템 및 이를 이용한 레티클 표면의 파티클제거방법
ATE503498T1 (de) 2002-06-21 2011-04-15 Novo Nordisk Healthcare Ag Pegylierte glykoformen von faktor vii
US7238677B2 (en) 2003-03-28 2007-07-03 Kimberly-Clark Worldwide, Inc. Prevention of urogenital infections
EP1697481A2 (en) * 2003-12-09 2006-09-06 Spherics, Inc. Bioadhesive polymers with catechol functionality
AU2005328670B2 (en) 2005-03-03 2011-08-11 Mannatech, Inc. Methods and compositions for modified release of nutritional supplements
US20100226855A1 (en) * 2006-03-02 2010-09-09 Spherics, Inc. Rate-Controlled Oral Dosage Formulations
US9744137B2 (en) * 2006-08-31 2017-08-29 Supernus Pharmaceuticals, Inc. Topiramate compositions and methods of enhancing its bioavailability
IL268475B (en) 2007-05-31 2022-08-01 Government Of The Us Secretary Of The Department Of Health And Human Services National Institutes Of N-acetyl mannosamine as a therapeutic agent
WO2009032605A2 (en) 2007-08-27 2009-03-12 Massachusetts Institute Of Technology Bi-functional polymer-attached inhibitors of influenza virus
WO2009137827A2 (en) 2008-05-09 2009-11-12 Tiara Pharmaceuticals, Inc. Controlled release of n-acetylcysteine (nac) for reduction of systemic and/or vascular inflammation
KR101116864B1 (ko) 2008-08-01 2012-02-29 주식회사 베네비오 고지혈증, 지방간 또는 비만의 예방 또는 치료용 조성물
US20100160363A1 (en) 2008-12-19 2010-06-24 Aaipharma Services Corp. Extended-release pharmaceutical formulations
US9241896B2 (en) 2008-12-19 2016-01-26 Ultragenyx Pharmaceutical Inc. Methods and formulations for treating sialic acid deficiencies
US20100159001A1 (en) 2008-12-19 2010-06-24 Cardinal John R Extended-Release Pharmaceutical Formulations
JP5626734B2 (ja) * 2009-05-15 2014-11-19 公益財団法人ヒューマンサイエンス振興財団 Ｇｎｅタンパク質の機能低下に起因する疾患の治療用医薬剤、食品組成物
JP5777712B2 (ja) 2010-07-13 2015-09-09 ウルトラジェニックス ファーマシューティカル インコーポレイテッド シアル酸欠乏症を治療するための方法および製剤
CA2849114C (en) 2011-10-24 2020-12-15 Ultragenyx Pharmaceutical Inc. Sialic acid analogs
BR112014017587A8 (pt) 2012-01-18 2017-07-04 Ultragenyx Pharmaceutical Inc métodos e formulações para o tratamento de deficiências de ácido siálico
CN107207552B (zh) 2015-01-28 2021-03-26 协和发酵生化株式会社 N-乙酰神经氨酸铵盐无水物的晶体及其制造方法
AR106025A1 (es) 2015-09-14 2017-12-06 Ultragenyx Pharmaceutical Inc Formas cristalinas de ácido siálico o una sal o solvato de este

Also Published As

Publication number Publication date
US20200131215A1 (en) 2020-04-30
US20190127409A1 (en) 2019-05-02
KR20140084277A (ko) 2014-07-04
US20130122094A1 (en) 2013-05-16
WO2013063149A1 (en) 2013-05-02
MX347541B (es) 2017-04-28
US8840926B2 (en) 2014-09-23
CA2849114C (en) 2020-12-15
US10457701B2 (en) 2019-10-29
AU2012328874A1 (en) 2014-04-10
HK1201067A1 (en) 2015-08-21
EP2771348B1 (en) 2020-05-20
US20160297846A1 (en) 2016-10-13
ES2807890T3 (es) 2021-02-24
CA2849114A1 (en) 2013-05-02
BR112014009760A2 (pt) 2017-04-18
JP2014530882A (ja) 2014-11-20
US9221858B2 (en) 2015-12-29
EP2771348A4 (en) 2015-09-09
IL231714A0 (en) 2014-05-28
US20150038693A1 (en) 2015-02-05
US10065981B2 (en) 2018-09-04
JP6196224B2 (ja) 2017-09-13
MX2014004928A (es) 2014-11-10
CN103974965A (zh) 2014-08-06
IL231714B (en) 2018-10-31
CN103974965B (zh) 2019-09-24
US10889607B2 (en) 2021-01-12
BR112014009760A8 (pt) 2018-01-16
EP2771348A1 (en) 2014-09-03
AU2012328874B2 (en) 2017-08-31
KR102049214B1 (ko) 2019-11-28

Similar Documents

Publication Publication Date Title
US10889607B2 (en) Sialic acid analogs
EP3253747B1 (en) 3-alkyl-4-amido-bicyclic [4,5,0]hydroxamic acids as hdac inhibitors
JP6616821B2 (ja) オートタキシンの置換スピロ環式阻害剤
KR870000357B1 (ko) 4-치환된-2-아제티디논 화합물의 제조 방법
AU2019351494B2 (en) Nitroxoline prodrug and use thereof
KR20050037559A (ko) 항바이러스성 ７-데아자 ｄ-뉴클레오시드 및 그의 용도
KR20250024077A (ko) Pan-kras 억제제의 전구약물
WO2012022121A1 (zh) 作为盐皮质激素受体拮抗剂的并环类化合物
JP7417519B2 (ja) チエノジアゼピン誘導体とその応用
CA3152690A1 (en) Compound as small molecule inhibitor pd-1/pd-l1 and application thereof
US20250340532A1 (en) Heterocyclic compound ccr4 inhibitor and user thereof
CA3121517A1 (en) Quaternary ammonium salts as inhibitors of trimethylamine production
JP2019515014A (ja) セコマクロライド化合物
JP2025524557A (ja) 二官能性化合物、該二官能性化合物を含む医薬組成物、およびこれらを使用したアンドロゲン受容体関連疾患の治療方法
CN117924106B (zh) 可电离脂质化合物
BRPI0520406B1 (pt) método de síntese de derivados de aminoácido-imidazol e compostos relacionados

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06T Formal requirements before examination [chapter 6.20 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B09X Republication of the decision to grant [chapter 9.1.3 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 24/10/2012, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.